Human aging is characterized by chronic, low-grade inflammation which is called "inflammaging." Inflammaging is a highly significant risk factor for both morbidity and mortality in the elderly people, as most, if not all, age-related diseases share an inflammatory pathogenesis. This inflammation significantly increases the risk of diseases such as cancer, Type II diabetes (insulin resistance), cardiovascular diseases (atherosclerosis, stroke, heart attack), sarcopenia (muscle loss), kidney disease, neurogenerative disease (Alzheimer’s and Parkinson’s disease).
AlloLife® is designed to eliminate the source of chronic inflammation which causes Imflammaging and subsequently “reset” the regulatory networks in order to suppress the chronic inflammation. AlloLife® paradoxically acts by first enhancing the immune status of a person. This enhanced immune status then acts to eliminate sub-clinical viral infection. Once eliminated, natural regulatory circuits initiate which down-regulate the chronic immune activation (especially innate monocyte immunity). This reset is believed to allow for healthy aging.
A key marker of inflammation is C-reactive Protein (CRP). Normally individuals do not have CRP in circulation, however inflammation can result in increasing CRP values. Proinflammatory cytokines also play an important role in inflammaging. Elevated levels of cytokines such as IL-1, IL-6 and TNF-α in the serum of the elderly are associated with disease, disability, and mortality. AlloLife® causes down-regulation of CRP levels and cytokines such as IL-1, IL-6 and TNF-alpha. Studies employing large patient cohorts provide evidence that CRP and these inflammatory monocyte-derived cytokines are reliable markers of inflammaging and appear to play a decisive role in aging. By reducing these markers, AlloLife® may decrease susceptibility to age-related diseases, allowing healthy aging.
The socio-economic impact of our aging population is a major looming crisis. However, a growing older population only becomes a burden on society when they develop chronic diseases which prevents them from working and if they require long-term assisted care and hospitalization. However, if the population remains healthy and active, they contribute and benefit the economy. The economic value of delayed aging is estimated to be $7.1 trillion over 50 years. Delayed aging means having an immunological age much younger than your chronical age. Thus, spending a larger proportion of one’s life in good health and free from frailty and disability. The costs of caring for older people will vary in the future depending on whether the elderly are in good or bad health. Poor health or disability at all ages are major drivers of health care expenditures. Our AlloLife® program is designed to provide individuals with a new tool that along with diet, exercise and smoking cessation and moderation of alcohol consumption can have a major impact on the quality of life.
Current health systems in almost all countries depend on intergenerational redistribution. However, as the population disproportionately becomes older, resulting in a shrinking tax base combined with increase in health costs, there will be greater and greater pressure on the system. AlloLife® provides a novel solution to this growing problem by potentially extending the health and productive life. We are seeking to partner with government payor programs and healthcare and life insurance companies in order to provide AlloLife® to their insured lives. Successfully preventing diseases of aging and providing extended healthy aging can significantly decrease the risk profiles and profits.
"Global aging will become not just the transcendent economic issue of the 21st century, but the transcendent political issue as well." Pete Peterson, former U.S. secretary of commerce and Deputy Chairman of the Federal Reserve Bank of New York